Business Context and Reporting Period
Spero Therapeutics, Inc. (SPRO) filed a Form 8-K on May 13, 2026, to report its financial results for the first quarter ended March 31, 2026. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. The document serves solely as a notification that the Q1 2026 results have been announced via a press release.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The text explicitly states that the information in the referenced press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q1 2026 financial figures.
- Verify cash runway and burn rate given the lack of revenue disclosure in the 8-K text.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm the status of the company's emerging growth company election and any related accounting transitions.